Platform

Far More Is Known About Disease Than Can Be Treated

Most validated disease targets remain unaddressed — known to science but unreachable with today’s medicines.

Unlocking and controlling them could transform the lives of millions of patients.

Challenging The Assumptions Of Druggability

Most small molecule drugs bind in deep, highly structured pockets within proteins. Valuable targets lacking these physical footholds for conventional molecules are deemed undruggable’.

Drug discovery has worked within a defined set of rules about chemical binding – until now.

The Right Modality

A Unique Biochemical Insight To Catalyze Binding

We see binding sites differently.

Given the right molecule, the surface of proteins can catalyze bond formation. What looks smooth and undruggable to others is a rich, catalytic landscape to us. The unique electronic signatures of our molecules enables privileged access to protein surfaces previously out of medicine’s reach.

The Right Data

The Richest Dataset In The World

Our industry leading drug discovery platform is designed to power AI with unrivaled data richness, throughput, and resolution – the potency of every molecule, measured against the entire proteome, at atomic precision.

A data generation engine running 247 to learn the rules of covalent bond formation and enable generatively designed medicines.

The Right Algorithms

The Next Frontier Of Generative Chemistry Starts With The Electron, Not The Atom

Bonds form when atoms share electrons.

Advances in AI and quantum chemistry are revolutionizing our ability to compute molecular electron clouds with unprecedented accuracy and scale. Our data is the map between high accuracy, synthetic quantum data and covalent bond formation to undruggable protein surfaces.

Combining innovations across artificial intelligence, quantum chemistry, and covalent drug discovery to generate medicines for any target and every patient.

Drug development pipeline showing therapeutic areas, target classes, mechanisms, partners, and development stages. Under Oncology: a bifunctional degrader targeting regulators in lead optimization phase, two PPI inhibitors (one targeting regulators, one targeting transcription factors) both in hit-to-lead phase, and a multi-target collaboration with various mechanisms through a partnership with Pfizer. Under I&I (Immunology and Inflammation): an allosteric inhibitor targeting sensors in the lead optimization phase.

The Entire Proteome Is Now Within Reach.

Our discovery pipeline is filled with first-in-class and first-in-mechanism programs in oncology, immunology, and other well-defined diseases.

We don’t just claim to be drugging the undruggable, we have proof.